Ethical Conflicts in Randomized Controlled Trials

Robert D. Truog, MD
Frances Glessner Lee Professor of Medical Ethics, Anaesthesia, & Pediatrics
Director, Center for Bioethics, Harvard Medical School
Senior Associate in Critical Care Medicine, Boston Children's Hospital
Extracorporeal Membrane Oxygenation and Conventional Medical Therapy in Neonates With Persistent Pulmonary Hypertension of the Newborn: A Prospective Randomized Study

P. Pearl O’Rourke, MD, Robert K. Crone, MD, Joseph P. Vacanti, MD, James H. Ware, PhD, Craig W. Lillehei, MD, Richard B. Parad, MD, and Michael F. Epstein, MD
Placing ECMO Cannulae at the Bedside
Nurse and ECMO Specialist at Bedside 24x7
Background to the Harvard Trial

• An RCT in the 1970s had shown ECMO not effective for ARDS in adults

• In the 1980s, Robert Bartlett used ECMO to treat newborns with PPHN

• Results were very impressive

• But, pediatricians were reluctant to adopt ECMO without convincing data from an RCT
Question #1

• Imagine you were Bob Bartlett

• Would you have sought to perform an RCT to demonstrate the superiority of ECMO to Conventional Medical Therapy (CMT)?

• Why or why not?
Poll #1

• YES: I would do an RCT to prove the superiority of ECMO over conventional medical therapy (CMT)

• NO: It would not be ethical for me to randomize patients to a control group, given my personal experience with ECMO
• Yes, I would do the RCT, because
  • Without a control group, we can never be sure if the new therapy is better
  • RCTs are the gold standard for convincing physicians to change their practice
  • By proving the superiority of ECMO, I can save the lives of many more babies – I have an ethical obligation to do the study

• No, I would not do an RCT
  • It would be unethical for me to randomize patients when I am convinced that one therapy is superior
  • It would be unethical for doctors and nurses to let a patient die when they think the patient could be saved
Extracorporeal Circulation in Neonatal Respiratory Failure: A Prospective Randomized Study

Robert H. Bartlett, MD, Dietrich W. Roloff, MD, Richard G. Cornell, PhD, Alice French Andrews, MD, Peter W. Dillon, MD, and Joseph B. Zwischenberger, MD
Question #2

• Imagine you were a neonatologist in Boston

• When you read this article, would you have told your hospital administrator that you needed to start an ECMO program?

• Why or why not?
Poll #2

• YES:
  This is a statistically significant trial – I should change my practice and create an ECMO program at my hospital

• NO:
  Regardless of the statistics, this trial does not convince me that ECMO is a superior therapy.
• Yes, I would change my practice, because
  • We need to trust statistics – since this trial result is statistically significant, we should change our practice

• No, I would not change my practice, because
  • The result is contingent upon the outcome of only one patient – if that patient had survived the trial might have gone differently
  • RCTs must have balanced (50/50) randomization or they are not valid
  • The trial should have been done at another center with unbiased physicians
“The clinical indications for this new and complex treatment remain undefined. Further randomized controlled trials... will be difficult but remain necessary.”
Extracorporeal Membrane Oxygenation and Conventional Medical Therapy in Neonates With Persistent Pulmonary Hypertension of the Newborn: A Prospective Randomized Study

P. Pearl O’Rourke, MD, Robert K. Crone, MD, Joseph P. Vacanti, MD, James H. Ware, PhD, Craig W. Lillehei, MD, Richard B. Parad, MD, and Michael F. Epstein, MD
The Harvard Neonatal ECMO Trial: Study Design

• Eligible newborns had PPHN and a predicted mortality of 85% based on retrospective data
• Phase I: 50/50 randomization until there were 4 deaths in one arm
• Phase II: Assign all patients to the more successful therapy, until there are 4 deaths in that arm or until statistical significance is achieved
• Seek consent only from those randomized to the experimental therapy
The Harvard Neonatal ECMO Trial: Results

<table>
<thead>
<tr>
<th>Phase</th>
<th>ECMO</th>
<th>CMT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase I</td>
<td>9 s, 0 d</td>
<td>6 s, 4 d</td>
</tr>
<tr>
<td>Phase II</td>
<td>19 s, 1 d</td>
<td></td>
</tr>
</tbody>
</table>
Healer versus Investigator

The Fundamental Conflict
The Fundamental Dilemma

• A dilemma confronts physician-investigators…

• As physicians they are dedicated to caring for their patients…

• As investigators they are dedicated to caring for their research…

• These two commitments conflict whenever an individual physician/investigator comes face to face with an individual patient/subject.  
  
  Jay Katz, 1993
HIRAM S. DUDSON
1930 - 1993
Member, Placebo Group
Possible Solution #1: Full Separation of Roles

“Researchers must give patients stark, bold, and dramatic signs that research is different from clinical care… instead of the white coats associated with medical care, investigators could wear red ones…”

Possible Solution #2: Personal Equipoise

• Requires that the investigator be personally unbiased between the treatment arms, “perfectly balanced on the edge of the sword”

• But, researchers usually “believe in” the treatments they study

• Requiring personal equipoise leaves investigators feeling either “guilty” or “cynical”
Possible solution #3: Clinical Equipoise

- Requires uncertainty within the medical community as a whole
  - “I believe that “A” is better, but if your appointment had been with my colleague down the hall, she would have recommended “B”
  - “So… would you agree to have your treatment determined by a coin flip, so that we can learn from this experience?”

- Harvard ECMO Trial
  - Likely that no single investigator was in personal equipoise
  - Freedman: the collective uncertainty represented clinical equipoise

Adaptive Randomization

Balancing Conflicting Obligations
Adaptive Randomization

• Definition: Deviating from “balanced” or 50/50 randomization, with more patients assigned to the therapy that is “leading” during the trial

• Betting on the horse who is out in front, before we know how the race will end
Adaptive Randomization

- Attempts to minimize number of patients assigned to the less-successful therapy

- Attempts to mitigate the conflict of healer versus investigator
  - In the Bartlett trial, 50/50 randomization was guaranteed only for the first patient
  - In the Harvard trial, 50/50 randomization was guaranteed until the 4th death in one arm
The Harvard trial was criticized from both directions

- No patients should have been assigned to CMT
  
  “The clear expectation was that more patients would die on conventional therapy. Was having an excess number of deaths balanced by the worth of the information gained? My answer is a resounding no.”
  
  Don Berry, U of Minnesota

- Not enough patients were assigned to CMT
  
  The researchers were so preoccupied with ethical problems that they stopped the conventional therapy too soon.

  Colin Begg, Memorial Sloan Kettering

  “There is a slightly hysterical view that we need to stop a study as soon as we have an idea which treatment might be better.

  Paul Meyer, U of Chicago

- Perhaps this approach was a good balance
Adaptive Clinical Trials
A Partial Remedy for the Therapeutic Misconception?

William J. Meurer, MD, MS
Roger J. Lewis, MD, PhD
Donald A. Berry, PhD

Although knowledge regarding the relative effectiveness of the treatments involved accumulates over the course of a clinical trial, beginning with a state of equipoise and having high confidence near the end, fixed assignment en-

Adaptive Trials in Clinical Research
Scientific and Ethical Issues to Consider

Rieke van der Graaf, PhD
Kit C. B. Roes, PhD
Johannes J. M. van Delden, MD, PhD

Scientific Validity
There are compelling reasons why adaptive trials may be superior to trials with fixed assignment en-

van der Graaf et al. JAMA 2012;307:2379
Meurer et al. JAMA 2012;307:2377
I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy

AD Barker, CC Sigman, GJ Kelloff, NM Hylton, DA Berry and LJ Esserman

I-SPY 2 (Investigation of Serial Studies to Predict Your therapeutic response with imaging and molecular analysis 2) is a process targeting the rapid, focused clinical development of paired oncologic therapies and biomarkers. The framework is an adaptive phase II clinical trial design in the neoadjuvant setting for women with locally advanced breast cancer. I-SPY 2 is a collaborative effort among academic investigators, the National Cancer Institute, the US Food and Drug Administration, and the pharmaceutical and biotechnology industries under the auspices of the Foundation for the National Institutes of Health Biomarkers Consortium.

treatment options remain limited. These patients continue to represent a disproportionately large fraction of those who die of their disease. Given that the standard of care for these women increasingly includes neoadjuvant therapy prior to surgical resection, this combination of group and setting represents a unique opportunity to learn how to tailor the treatment to patients with high-risk breast cancers.

Cancer research from the past decade has shown that breast cancer is a number of heterogeneous diseases; this finding suggests that directing drugs to molecular pathways that characterize the disease in subsets of patients will improve treatment efficacy. Currently, however, most phase II and III trials of new
Randomized Consent
(Zelen Randomization)
Easing the Psychological Burdens
Conventional RCT

- Patient Eligible
- Informed Consent
  - Yes
    - RANDOMIZE
    - A
    - B
  - No
    - Dropped

Marvin Zelen
Lemuel Shattuck Research Professor of Statistical Science and Member of the Faculty of Arts and Sciences
Department of Biostatistics

Harvard School of Public Health
Randomized Consent

Patient Eligible

 RANDOMIZE

Do not seek consent

Seek consent: Will you accept B?

No

Yes

A

A

B
Randomized Consent

Newborn Eligible

Randomize

Do not seek consent

CMT

Seek consent: Will you accept ECMO?

Yes ➞ ECMO

No ➞ CMT

CMT
Question #3

- Imagine you were on the IRB at Boston Children’s Hospital when this study was proposed

- Would you have approved the Zelen randomization scheme?

- Why or why not?
Poll #3

- YES: I would have voted to approve the Zelen randomization scheme
- NO: I would not have voted to approve the Zelen randomization scheme
• Yes, I would have voted to approve the scheme, because:
  • The control babies were not really research subjects – their care was unchanged from what it would have been if the study had never been performed
  • It would have been cruel to tell parents that a treatment that might have saved their baby’s life was available, but they couldn’t have it.

• No, I would not have voted to approve the scheme, because:
  • It is always unethical to use data from patients without their informed consent
  • It is wrong to use data without the patient’s knowledge
  • Intentionally withholding information from patients is deceptive, and deception is always wrong
The NIH Office for Protection from Research Risks (OPRR/OHRP) reprimanded the hospital

The hospital IRB “made decisions that rightfully belonged to the parents. They really blew it.”

Charles McCarthy, Director of OPRR (OHRP)
My take...

• On one hand:
  • The clinical management of the control patients was not impacted by the trial
  • I’m not convinced that parents would have found it valuable or useful to be told about a treatment option that was not available to them
  • Consent is routinely waived for studies that only involve anonymous chart review, which was the case for the control patients in this study
My take...

• On the other hand:
  • What if the parents of one of the control patients who died later learned that their child had been a participant in this study?
  • In order to maintain trust in the research enterprise, we need to be open and transparent about study design.
Are RCTs the only way to learn?
Approaches to Learning: Ascending Order of Confidence

- Meta-analyses
- Randomized Controlled Trials
- Case / Control Observational Studies
- Databases
- Case Series with Historical Controls
- Case Series with Literature Controls
- Case Series without Controls
- Anecdotal Case Reports
Question #4

- Given the results of these trials, are you now convinced, beyond a reasonable doubt, that ECMO is superior to conventional therapy?
Poll #4

• **YES:**
  Based on the data from the two trials, I am convinced that ECMO is superior in the treatment of newborns with life-threatening PPHN

• **NO:**
  I am not convinced – more RCTs need to be done
The UK Neonatal ECMO Trial

UK collaborative randomised trial of neonatal extracorporeal membrane oxygenation

- The existing “RCTs of neonatal ECMO… suggested reductions in mortality but were not conclusive.”
- Because they “used adaptive designs, which may have introduced bias…”

Field et al. UK collaborative randomised trial of neonatal extracorporeal membrane oxygenation. Lancet 1996;348:75-82
The UK Neonatal ECMO Trial

- 1993-1995: 185 neonates randomized to ECMO vs CMT
- Trial stopped early by DSMB,
  - ECMO survival 60/93 = 65%
  - CMT survival 38/92 = 41%, p<0.0005
- Were 22 babies unnecessarily “sacrificed”? 
Conclusions

• The conflict between clinician and investigator is profound and can never be entirely eliminated

• Adaptive randomization is one way to balance the competing obligations

• Zelen randomization reduces the psychological burdens on investigators and subjects, but is probably unacceptable

• RCTs are usually the best approach for evaluating new therapies, but in many cases designs that are less ethically challenging can be convincing and should be considered.